T. Suedhoff

633 total citations
14 papers, 464 citations indexed

About

T. Suedhoff is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, T. Suedhoff has authored 14 papers receiving a total of 464 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 4 papers in Hepatology. Recurrent topics in T. Suedhoff's work include Renal cell carcinoma treatment (4 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). T. Suedhoff is often cited by papers focused on Renal cell carcinoma treatment (4 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). T. Suedhoff collaborates with scholars based in Germany and Austria. T. Suedhoff's co-authors include Dieter Buchheidt, Wolfgang Seifarth, J. Ritter, Heyko Skladny, M. Baldus, Rüediger Hehlmann, Corinna Baust, Torsten Liersch, Gunnar Folprecht and Wolf O. Bechstein and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Infectious Diseases and Annals of Oncology.

In The Last Decade

T. Suedhoff

13 papers receiving 450 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
T. Suedhoff Germany 8 229 195 187 140 97 14 464
Gudrun Russ Austria 10 122 0.5× 112 0.6× 120 0.6× 19 0.1× 57 0.6× 14 283
J. Toyota Japan 9 38 0.2× 189 1.0× 100 0.5× 284 2.0× 9 0.1× 16 368
Yasushi Shiratori Japan 8 48 0.2× 161 0.8× 30 0.2× 208 1.5× 16 0.2× 11 430
E. Castellà Spain 12 134 0.6× 56 0.3× 53 0.3× 21 0.1× 153 1.6× 19 508
M Favret Italy 8 105 0.5× 346 1.8× 115 0.6× 349 2.5× 121 1.2× 11 638
Anne Nihtinen Finland 12 102 0.4× 109 0.6× 93 0.5× 12 0.1× 25 0.3× 24 377
Takayuki Tabayashi Japan 12 100 0.4× 74 0.4× 68 0.4× 17 0.1× 23 0.2× 43 365
Pamela S. Bogert United States 6 73 0.3× 93 0.5× 20 0.1× 148 1.1× 27 0.3× 8 477
Yoshihiro Edamoto Japan 11 115 0.5× 222 1.1× 47 0.3× 195 1.4× 30 0.3× 27 474
Minas P. Economides United States 11 102 0.4× 150 0.8× 62 0.3× 148 1.1× 11 0.1× 27 344

Countries citing papers authored by T. Suedhoff

Since Specialization
Citations

This map shows the geographic impact of T. Suedhoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Suedhoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Suedhoff more than expected).

Fields of papers citing papers by T. Suedhoff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Suedhoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Suedhoff. The network helps show where T. Suedhoff may publish in the future.

Co-authorship network of co-authors of T. Suedhoff

This figure shows the co-authorship network connecting the top 25 collaborators of T. Suedhoff. A scholar is included among the top collaborators of T. Suedhoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Suedhoff. T. Suedhoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Vogelhuber, Martin, Susan Feyerabend, Arnulf Stenzl, et al.. (2014). Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan. Cancer Microenvironment. 8(1). 33–41. 12 indexed citations
2.
Folprecht, Gunnar, Thomas Gruenberger, Wolf O. Bechstein, et al.. (2014). Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Annals of Oncology. 25(5). 1018–1025. 174 indexed citations
3.
Folprecht, Gunnar, Thomas Gruenberger, Wolf O. Bechstein, et al.. (2013). Cetuximab and chemotherapy in the treatment of patients with initially “nonresectable” colorectal (CRC) liver metastases: Long-term follow-up of the CELIM trial.. Journal of Clinical Oncology. 31(15_suppl). 3538–3538. 5 indexed citations
4.
Reinwald, Mark, Michael Hummel, Birgit Spieß, et al.. (2012). Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies. Journal of Antimicrobial Chemotherapy. 67(9). 2260–2267. 80 indexed citations
5.
Folprecht, Gunnar, Thomas Gruenberger, Wolf O. Bechstein, et al.. (2012). Survival with cetuximab/FOLFOX or cetuximab/FOLFIRI of patients with nonresectable colorectal liver metastases in the CELIM study.. Journal of Clinical Oncology. 30(4_suppl). 540–540. 12 indexed citations
6.
Walter, Bernhard, Martin Vogelhuber, Jochen Grassinger, et al.. (2011). Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial. Medical Oncology. 29(2). 799–805. 25 indexed citations
7.
8.
Folprecht, Gunnar, Thomas Gruenberger, Wolf O. Bechstein, et al.. (2011). 6009 POSTER DISCUSSION Progression Free and Overall Survival After Neoadjuvant Treatment of Colorectal Liver Metastases With Cetuximab Plus FOLFOX or FOLFIRI – Results of the CELIM Study. European Journal of Cancer. 47. S394–S394. 6 indexed citations
9.
Reichle, Albrecht, Jochen Grassinger, K. Bross, et al.. (2007). C-reactive Protein in Patients with Metastatic Clear Cell Renal Carcinoma: An Important Biomarker for Tumor-associated Inflammation.. PubMed. 1. 87–98. 16 indexed citations
10.
Reichle, Albrecht, Jochen Grassinger, K. Bross, et al.. (2006). Effect of anti-inflammatory therapy in patients with metastatic renal cell carcinoma on clinical response. Journal of Clinical Oncology. 24(18_suppl). 14500–14500.
11.
Reichle, Albrecht, Jochen Grassinger, K. Bross, et al.. (2006). C-reactive Protein in Patients with Metastatic Clear Cell Renal Carcinoma: An Important Biomarker for Tumor-associated Inflammation. Biomarker Insights. 1. 2137016740–2137016740. 7 indexed citations
12.
Buchheidt, Dieter, Corinna Baust, Heyko Skladny, et al.. (2001). Detection ofAspergillusSpecies in Blood and Bronchoalveolar Lavage Samples from Immunocompromised Patients by Means of 2‐Step Polymerase Chain Reaction: Clinical Results. Clinical Infectious Diseases. 33(4). 428–435. 117 indexed citations
13.
Heyll, A., Ulrich Germing, A. Wehmeier, et al.. (1998). Dyshematopoiesis in De Novo Acute Myeloid Leukemia: Cell Biological Features and Prognostic Significance. Leukemia & lymphoma. 29(5-6). 523–531. 5 indexed citations
14.
Karthaus, Meinolf, H. Wolf, Gerlinde Egerer, et al.. (1998). Ceftriaxone in the Treatment of Solid Tumour Patients with Febrile Neutropenia. Oncology Research and Treatment. 21(3). 212–216. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gudrun Russ Breakdown of academic impact, for papers by J. Toyota Breakdown of academic impact, for papers by Yasushi Shiratori Breakdown of academic impact, for papers by E. Castellà Breakdown of academic impact, for papers by M Favret Breakdown of academic impact, for papers by Anne Nihtinen Breakdown of academic impact, for papers by Takayuki Tabayashi Breakdown of academic impact, for papers by Pamela S. Bogert Breakdown of academic impact, for papers by Yoshihiro Edamoto Breakdown of academic impact, for papers by Minas P. Economides
Rankless by CCL
2026